| Title: |
Sprague-Dawley rats treated with celecoxib to prevent induced cancer. [original title: Chemoprevention of the hepatocarcinogenesis by celecoxib]
|
| Organism(s): |
Rattus norvegicus
|
| Description: |
Male rats were treated with diethylnitrosamine and 2-acetylaminofluorene to induce cancer. 4 rats were fed celecoxib throughout, starting 1 week before induction; 4 rats were fed celecoxib starting 18 days after induction, and 4 rats were not given celecoxib. After 25 days, livers were harvested and subjected to transcriptional profiling. [original (edited) description: Microarray analysis is a useful methodology to identify target genes modulated by anticancer drugs. Here, celecoxib['s] effect on gene expression profiles was evaluated in the modified resistant hepatocyte model. Animals subjected to carcinogenic treatment were fed [a] diet containing 1500 ppm of celecoxib. Two schemes of celecoxib administration were designed. In the progression protocol, celecoxib was administrated between days 18 and 25 post-cancer initiation, [for] a total of 8 celecoxib treatment days, when well established preneoplastic lesions start to appear. In the initiation protocol, celecoxib was administrated from one week before until 25 days after ... cancer initiation, [for] a total of 32 celecoxib treatment days. A rat group was subjected only to the carcinogenic treatment as cancer positive control. Gene expression profiles of all groups were compared to a negative untreated control. The evaluation of gene expression profiles permitted us to identify new target genes that are modulated by celecoxib treatment. A possible mechanism of celecoxib chemoprevention of hepatocarcinogenesis is proposed. 9-week-old Sprague-Dawley rats, 4 rats per group, were subjected to Semple-Roberts' modified hepatocarcinogenesis protocol and sacrificed 25 days post-initiation. In celecoxib-treated groups, celecoxib was administrated mixed in diet at 1500 ppm. Negative and positive cancer progression controls were included to compare gene expression profiles. Microarray analysis was performed on liver samples, one replicate per rat, using dye swap.]
|
| Design(s): |
transcription profiling by array
|
| Experimental factor(s): |
|
| treatment
4
recorded
|
|
|
|
None
Carcinogenic plus celecoxib in progression stage
Carcinogenic plus celecoxib since a week before initiation stage.
Carcinogenic Treatment
|
|
| Publication(s): |
Arellanes-Robledo J, Salcido-Neyoy ME, Márquez-Quiñones A, García-Román R, Beltrán-Ramírez O, Le Berre V, Sokol S, François JM, Villa-Treviño S
Celecoxib activates Stat5 and restores or increases the expression of growth hormone-regulated genes in hepatocarcinogenesis.
PubMed:20145537
|
| Sample attribute(s): |
|
| Material Type
1
recorded
|
|
|
|
total RNA
|
| celecoxib
1
recorded
|
|
|
|
|
| diethylnitrosamine
1
recorded
|
|
|
|
N-nitrosodiethylamine
|
| Gender
1
recorded
|
|
|
|
Male
|
| age
1
recorded
|
|
|
|
9 week
|
| Tissue
1
recorded
|
|
|
|
liver
|
| Label
2
recorded
|
|
|
|
Cy3
Cy5
|
| 2acetylaminofluorene
1
recorded
|
|
|
|
2-acetamidofluorene
|
| duration of celecoxib exposure
3
recorded
|
|
|
|
7 day
32 day
0 day
|
| Strain
1
recorded
|
|
|
|
Sprague Dawley
|
| Treatment
4
recorded
|
|
|
|
None
Carcinogenic treatment plus celecoxib in progression stage
Carcinogenic treatment plus celecoxib since a week before initiation stage.
Carcinogenic
|
| Organism
1
recorded
|
|
|
|
Rattus norvegicus
|
|
| Contact(s): |
Serguei Sokol Olga Beltran-RamirezRebeca Garcia-RomanAdriana Marquez-QuiñonesMartha Salcido-NeyoyJaime Arellanes-RobledoAdriana Marquez-QuiñonesSaul Villa-TreviñoVeronique LeBerreJean-Marie François
|
| Release Date: |
7/10/2009
|
| Submission Date: |
|
| Metadata Downloads |
Download Study Metadata as ISAtabDownload Study Metadata as ISAtab
|
| Assay Downloads |
| transcription profiling using DNA microarray
|
|
| 12 assays |
|
|
|
|
